SEC Tracker
Get the app

Pacira BioSciences PCRX

Pacira BioSciences Q3 FY25: revenue $179.5M, up 6%; diluted EPS $0.12

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Pacira BioSciences reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$179.5M+6% from $168.6M in Q3 FY2410-Q income statement, on EDGAR
  2. Net income$5.4MAgainst −$143.5M in Q3 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.12Against −$3.11 in Q3 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$147.6M−40% from $246.0M in Q3 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$60.8M+13% from $53.9M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Pacira BioSciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  3. Geron GERN public float $861M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025